Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes
Elisabetta Sauta, Marie Robin, Matteo Bersanelli, et al.
Journal of Clinical Oncology (2023) Vol. 41, Iss. 15, pp. 2827-2842
Open Access | Times Cited: 63

Showing 51-75 of 63 citing articles:

Validation and improvement of the molecular international prognostic scoring system in Chinese patients with myelodysplastic syndromes
Nanfang Huang, Song Yang, Lingyun Wu, et al.
Annals of Hematology (2024)
Closed Access
Advancing Drug Development in Myelodysplastic Syndromes
Alain Mina, Kathy L. McGraw, Lea Cunningham, et al.
Blood Advances (2024)
Open Access
Genomic Stratification of Hematological Malignancies
Pauline Robbe, Anna Schuh
HemaSphere (2023) Vol. 7, Iss. 6, pp. e902-e902
Open Access | Times Cited: 1
Performance of IPSS‐M in patients with myelodysplastic syndrome after hypomethylating agent failure
Samuel Urrutia, Kelly S. Chien, Ziyi Li, et al.
American Journal of Hematology (2023) Vol. 98, Iss. 10
Open Access | Times Cited: 1
Next-generation therapy for lower-risk MDS
Marie Sébert
Hematology (2023) Vol. 2023, Iss. 1, pp. 59-64
Closed Access | Times Cited: 1
Frontline treatment options for higher-risk MDS: can we move past azacitidine?
David A. Sallman, Zhuoer Xie
Hematology (2023) Vol. 2023, Iss. 1, pp. 65-72
Closed Access | Times Cited: 1
When to use which molecular prognostic scoring system in the management of patients with MDS?
Tariq Kewan, Jan Philipp Bewersdorf, Carmelo Gurnari, et al.
Best Practice & Research Clinical Haematology (2023) Vol. 36, Iss. 4, pp. 101517-101517
Closed Access
How to classify risk based on clinical and molecular modeling: integrating molecular markers in the risk assessment of myelodysplastic syndrome
Rena R. Xian
Hematology (2023) Vol. 2023, Iss. 1, pp. 51-58
Closed Access
Treatment Considerations of Myelodysplastic Syndromes/Neoplasms for Pathologists
Yazan F. Madanat, Amer M. Zeidan
Clinics in Laboratory Medicine (2023) Vol. 43, Iss. 4, pp. 685-698
Closed Access
Miyelodisplastik sendrom tanili hastalarin retrospektif değerlendirilmesi
Ferda CAN, İmdat Dilek
Turkish Journal of Clinics and Laboratory (2023) Vol. 14, Iss. 3, pp. 508-513
Open Access
Updates on risk stratification and management of lower-risk myelodysplastic syndromes/neoplasms
Talha Badar, Yazan F. Madanat, Amer M. Zeidan
Future Oncology (2023) Vol. 19, Iss. 27, pp. 1879-1891
Closed Access
MDS/CMML from resource‐limited region: Characteristics and comparison to tertiary reference European center
Anna Sevoyan, A. Mékinian, Fatiha Chermat, et al.
European Journal Of Haematology (2023) Vol. 112, Iss. 2, pp. 296-300
Open Access
Neueste Erkenntnisse zum myelodysplastischen Syndrom
Verena Petzer, Dominik Wolf‎
DMW - Deutsche Medizinische Wochenschrift (2023) Vol. 148, Iss. 22, pp. 1431-1436
Closed Access
Reply to R. Sun et al
J. Moore, Aida Santaolalla, Mieke Van Hemelrijck, et al.
Journal of Clinical Oncology (2023)
Open Access
Pulmonary infection associated with immune dysfunction is associated with poor prognosis in patients with myelodysplastic syndrome accompanied by TP53 abnormalities
Yi Chen, Jing Zheng, Yanyan Qiu, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access
Previous Page - Page 3

Scroll to top